Product Details

Purity

≥ 95% as determined by SDS-PAGE.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

①Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/mL can bind Anti-TNFRSF17 recombinant antibody (CSB-RA023974MA1HU). The EC50 is 5.652-7.215 ng/mL.
②Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/mL can bind Anti-TNFRSF17 recombinant antibody (CSB-RA023974MA3HU). The EC50 is 2.296-2.754ng/mL.
③Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/mL can bind Anti-TNFRSF17 recombinant antibody (CSB-RA023974MA4HU). The EC50 is 14.97-19.19 ng/mL.
④Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/mL can bind Human TNFSF13 protein (CSB-MP023989HU). The EC50 is 4.217-5.674 ng/mL.
⑤Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/mL can bind Human TNFSF13B protein (CSB-MP897523HU1). The EC50 is 4.346-5.534 ng/mL.

Target Names

TNFRSF17

Uniprot No.

Q02223

Alternative Names

B-cell maturation protein (CD_antigen: CD269)(BCM) (BCMA)

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

1-54aa

Target Protein Sequence

MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA

Mol. Weight

7.6 kDa

Protein Length

Partial

Tag Info

C-terminal 10xHis-tagged

Form

Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

Lyophilized from a 0.2 μm sterile filtered PBS, 6% Trehalose, pH 7.4

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

BCMA serves as a critical survival receptor on plasma cells and multiple myeloma cells, making it a high-priority target for CAR-T and antibody-drug conjugate therapies in hematologic malignancies. This mammalian-expressed fragment spanning residues 1–54 captures the extracellular ligand-binding domain and demonstrates robust binding to its natural ligands APRIL (TNFSF13) and BAFF (TNFSF13B) with EC50 values of 4.2–5.7 ng/mL and 4.3–5.5 ng/mL respectively, confirming native-like conformational integrity essential for physiologically relevant interaction studies. The protein also binds three distinct anti-BCMA recombinant antibodies with EC50 values ranging from 2.3 to 19.2 ng/mL, providing quantitative benchmarks for therapeutic antibody epitope mapping, competitive inhibition assays, and blocking antibody screening in CAR-T development workflows. With purity exceeding 95% by SDS-PAGE and endotoxin below 1.0 EU/μg, this reagent supports high-sensitivity binding assays including ELISA, surface plasmon resonance, and bio-layer interferometry for affinity characterization and drug discovery applications targeting the BCMA pathway.

Target Background

Function

Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK.

Gene References into Functions

Expression patterns of BAFF and its receptor BCMA differ according to lupus nephritis class. PMID: 29087261
High BCMA expression is associated with primary central nervous system lymphoma. PMID: 28521029
soluble BCMA sequesters circulating BAFF, thereby preventing it from performing its signaling to stimulate normal B-cell and plasma cell development, resulting in reduced polyclonal antibody levels in multiple myeloma patients. PMID: 26960399
Studied expression of B-cell maturation antigen (BCMA) in osteoblasts and the toxic effect of chromium on its expression; found BCMA is involved in osteogenesis of osteoblasts; chromium downregulates expression of BCMA in osteoblasts. PMID: 26011700
BCMA has other contributors for ligands binding except DxL motif. The affinity of BCMA for APRIL higher than for BAFF may be caused by the segment outside of the conservative DxL motif. Moreover, the exposition of new binding modes of BCMA2 interacting with APRIL may establish the foundation of designing novel drugs in the future PMID: 28260502
New molecular mechanisms of in vivo Multiple Myeloma (MM) growth and immunosuppression critically dependent on BCMA and APRIL in the Bone marrow microenvironment, further supporting targeting this prominent pathway in MM. PMID: 27127303
We have identified a specific serum protein, BCMA, as a novel independent marker for both monitoring and predicting outcomes for MM patients. We have shown that sBCMA is elevated in MM patients, and can be used to follow their disease status, PFS and OS. PMID: 28034989
The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in non-Hodgkin lymphoma patients were significantly higher than in healthy controls. PMID: 28028945
Decreased BCMA expression on peripheral B cells according to severe disease activity suggests that BCMA plays an important regulating role in B-cell hyperactivity and immune tolerance homeostasis in systemic lupus erythematosus patients PMID: 26424128
results suggest that Akt and JNK pathways are involved in the regulation of B-cell maturation antigen (BCMA) PMID: 26914861
shedding of BCMA by gamma-secretase controls plasma cells in the bone marrow and yields a potential biomarker for B-cell involvement in human autoimmune diseases PMID: 26065893
elevated serum levels in patients with Behcet's disease PMID: 25759827
Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. PMID: 25301447
High BCMA expression is associated with breast cancer. PMID: 25750171
BAFF and APRIL as well as their cognate receptors (BCMA, TACI) correlate with glioma grade. (Meta-analysis) PMID: 24376672
The B cell maturation antigen (BCMA) is a tumor necrosis family receptor member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF family and a proliferation inducing ligand. PMID: 23237506
Activation of B cells through BCMA regulates spinal cord injury-induced autoimmunity via a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF). PMID: 23088438
Data indicate that MAGE3, Survivin and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients. PMID: 23728352
Data indicate that B-cell maturation antigen (BCMA) is a suitable target for chimeric antigen receptor (CAR)-expressing T cells, and adoptive transfer of anti-BCMA-CAR-expressing T cells is a promising new strategy for treating multiple myeloma. PMID: 23344265
B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42. PMID: 23776238
the effect of APRIL is mediated via BCMA, which does not activate the classical NF-kappaB pathway, whereas it induces a novel signaling pathway, which involves JNK2 phosphorylation, FOXO3A activation, and GADD45 transcription PMID: 23071284
Serum BCMA levels were higher among patients with progressive disease than those with responsive disease. Overall survival was shorter among patients whose serum BCMA levels were above the median. PMID: 22804669
TNFRSF17 may be a candidate gene associated with the pathogenesis of colon cancer. PMID: 22108903
These data advance BCMA as an inflammation-related TNF superfamily member in keratinocytes, of potential importance in the management of inflammatory skin conditions. PMID: 22166983
primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and TACI PMID: 21687682
This is the first study, presenting together the TNFSF members APRIL, BAFF, TWEAK and their receptors in different areas of normal renal tissue and renal cell carcinoma. PMID: 21483105
Signaling through BCMA enhances B cell activation following exposure to TLR9 agonists, and increased expression in SLE may contribute to the production of IgG autoantibodies. PMID: 21250838
genetic polymorphisms are associated with gastrointestinal disorders PMID: 20016944
Expression of BCMA, TACI, and BAFF-R by multiple myeloma cells support cell growth and survival. PMID: 14512299
APRIL.TACI_d2 and APRIL.BCMA complexes together reveal the mechanism by which TACI engages high affinity ligand binding through a single cysteine-rich domain PMID: 15542592
BCMA is a target of donor B-cell immunity in patients with myeloma who respond to Donor lymphocyte infusions PMID: 15692072
Review. APRIL interactions with BCMA likely govern memory B cell populations. PMID: 16919470
Review. Direct BAFF/APRIL signalling in T cells and/or T cell modulation in response to a BAFF-modified B cell compartment may play an important role in inflammation and immunomodulation. PMID: 16931039
The BCMA inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. PMID: 16960154
BCMA TVs were observed only in some CD19+ cell samples. PMID: 17825416
rheumatoid arthritis fibroblast like synoviocytes are stimulated by APRIL and express the APRIL receptor BCMA PMID: 17968879
Expression of B cell maturation Ag (BCMA) is also highly regulated and we demonstrate that BCMA expression is only acquired in MB cells and in a manner accompanied by loss of BAFF-R expression. PMID: 18025170
we observed APRIL expression, together with TACI and BCMA in gut-associated lymphoid tissue, lamina propria, and in the epithelium of stomach, small and large intestine, and rectum. PMID: 19741596

Hide All

Involvement in disease

A chromosomal aberration involving TNFRSF17 is found in a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(4;16)(q26;p13) with IL2.

Subcellular Location

Cell membrane; Single-pass type III membrane protein. Endomembrane system; Single-pass type III membrane protein. Note=Perinuclear Golgi-like structures.

Tissue Specificity

Expressed in mature B-cells, but not in T-cells or monocytes.

Database Links

HGNC: 11913

OMIM: 109545

KEGG: hsa:608

STRING: 9606.ENSP00000053243

UniGene: Hs.2556

Code	CSB-MP023974HU1d7
Abbreviation	Recombinant Human TNFRSF17 protein, partial (Active)
MSDS	MSDS Datasheet
Size	$138
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Activity Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/ml can bind Anti-TNFRSF17 recombinant antibody (CSB-RA023974MA1HU). The EC₅₀ is 5.652-7.215 ng/mL. Biological Activity Assay Activity Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/ml can bind Anti-TNFRSF17 recombinant antibody (CSB-RA023974MA3HU). The EC₅₀ is 2.296-2.754ng/mL. Biological Activity Assay Activity Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/ml can bind Anti-TNFRSF17 recombinant antibody (CSB-RA023974MA4HU). The EC₅₀ is 14.97-19.19 ng/mL. Biological Activity Assay Activity Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/ml can bind Human TNFSF13 protein (CSB-MP023989HU). The EC₅₀ is 4.217-5.674 ng/mL. Biological Activity Assay Activity Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF17 protein at 2 μg/ml can bind Human TNFSF13B protein (CSB-MP897523HU1). The EC₅₀ is 4.346-5.534 ng/mL. Biological Activity Assay
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human Tumor necrosis factor receptor superfamily member 17 (TNFRSF17), partial (Active)

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage